دورية أكاديمية
The virtue of training: extending phage host spectra against vancomycin-resistant Enterococcus faecium strains using the Appelmans method.
| العنوان: | The virtue of training: extending phage host spectra against vancomycin-resistant Enterococcus faecium strains using the Appelmans method. |
|---|---|
| المؤلفون: | Lossouarn J; Université Paris-Saclay, INRAE, AgroParisTech, Micalis Institute, Jouy-en-Josas, France., Beurrier E; Université Paris-Saclay, INRAE, AgroParisTech, Micalis Institute, Jouy-en-Josas, France., Bouteau A; Université Paris-Saclay, INRAE, AgroParisTech, Micalis Institute, Jouy-en-Josas, France., Moncaut E; Université Paris-Saclay, INRAE, AgroParisTech, Micalis Institute, Jouy-en-Josas, France., Sir Silmane M; Université Paris-Saclay, INRAE, AgroParisTech, Micalis Institute, Jouy-en-Josas, France., Portalier H; Université Paris-Saclay, INRAE, AgroParisTech, Micalis Institute, Jouy-en-Josas, France., Zouari A; CHU de Rennes, Service de Bactériologie-Hygiène Hospitalière et CNR de la Résistance aux Antibiotiques (laboratoire associé 'Entérocoques'), Rennes, France., Cattoir V; CHU de Rennes, Service de Bactériologie-Hygiène Hospitalière et CNR de la Résistance aux Antibiotiques (laboratoire associé 'Entérocoques'), Rennes, France.; Université de Rennes, INSERM, UMR_S1230 BRM, Rennes, France., Serror P; Université Paris-Saclay, INRAE, AgroParisTech, Micalis Institute, Jouy-en-Josas, France., Petit M-A; Université Paris-Saclay, INRAE, AgroParisTech, Micalis Institute, Jouy-en-Josas, France. |
| المصدر: | Antimicrobial agents and chemotherapy [Antimicrob Agents Chemother] 2024 May 02; Vol. 68 (5), pp. e0143923. Date of Electronic Publication: 2024 Apr 09. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: American Society for Microbiology Country of Publication: United States NLM ID: 0315061 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1098-6596 (Electronic) Linking ISSN: 00664804 NLM ISO Abbreviation: Antimicrob Agents Chemother Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Washington, American Society for Microbiology |
| مواضيع طبية MeSH: | Enterococcus faecium*/drug effects , Bacteriophages*/genetics , Vancomycin-Resistant Enterococci*/drug effects , Host Specificity*, Phage Therapy/methods ; Gram-Positive Bacterial Infections/microbiology ; Vancomycin Resistance ; Vancomycin/pharmacology ; Humans ; Anti-Bacterial Agents/pharmacology |
| مستخلص: | Phage therapy has (re)emerged as a serious possibility for combating multidrug-resistant bacterial infections, including those caused by vancomycin-resistant Enterococcus faecium strains. These opportunistic pathogens belong to a specific clonal complex 17, against which relatively few phages have been screened. We isolated a collection of 21 virulent phages growing on these vancomycin-resistant isolates. Each of these phages harbored a typical narrow plaquing host range, lysing at most 5 strains and covering together 10 strains of our panel of 14 clinical isolates. To enlarge the host spectrum of our phages, the Appelmans protocol was used. We mixed four out of our most complementary phages in a cocktail that we iteratively grew on eight naive strains from our panel, of which six were initially refractory to at least three of the combined phages. Fifteen successive passages permitted to significantly improve the lytic activity of the cocktail, from which phages with extended host ranges within the E. faecium species could be isolated. A single evolved phage able to kill up to 10 of the 14 initial E. faecium strains was obtained, and it barely infected nearby species. All evolved phages had acquired point mutations or a recombination event in the tail fiber genetic region, suggesting these genes might have driven phage evolution by contributing to their extended host spectra. Competing Interests: The authors declare no conflict of interest. |
| References: | Viruses. 2023 Jan 10;15(1):. (PMID: 36680236) Curr Opin Biotechnol. 2021 Apr;68:115-123. (PMID: 33202354) PLoS One. 2011;6(12):e29023. (PMID: 22194979) Microbiome. 2018 Feb 20;6(1):38. (PMID: 29458427) J Comput Biol. 2012 May;19(5):455-77. (PMID: 22506599) Methods Mol Biol. 2009;501:175-202. (PMID: 19066822) J Gen Virol. 2014 Nov;95(Pt 11):2565-2575. (PMID: 25078302) Pharmaceuticals (Basel). 2021 Oct 03;14(10):. (PMID: 34681243) Pharmaceuticals (Basel). 2019 Mar 11;12(1):. (PMID: 30862020) Nat Rev Microbiol. 2018 Dec;16(12):760-773. (PMID: 30104690) BMC Genomics. 2014 Nov 27;15:1027. (PMID: 25428721) Sci Rep. 2017 Aug 31;7(1):10164. (PMID: 28860505) Sci Rep. 2016 Oct 04;6:34338. (PMID: 27698408) J Mol Biol. 2018 Jul 20;430(15):2237-2243. (PMID: 29258817) Virus Genes. 2023 Oct;59(5):763-774. (PMID: 37422898) Antimicrob Agents Chemother. 2021 Mar 1;65(5):. (PMID: 33649110) J Gen Virol. 2018 Sep;99(9):1331-1343. (PMID: 30016225) Nucleic Acids Res. 2020 Jan 8;48(D1):D265-D268. (PMID: 31777944) ISME Commun. 2021 Oct 25;1(1):55. (PMID: 37938642) Viruses. 2019 Jan 10;11(1):. (PMID: 30634666) Clin Microbiol Rev. 2019 Jan 16;32(2):. (PMID: 30651225) J Antimicrob Chemother. 2019 Jun 1;74(6):1473-1476. (PMID: 30863844) Front Microbiol. 2016 Sep 08;7:1352. (PMID: 27660623) J Bacteriol. 1976 Mar;125(3):1120-6. (PMID: 815237) NAR Genom Bioinform. 2021 Aug 05;3(3):lqab067. (PMID: 34377978) Microbiol Spectr. 2014 Nov;5(6):. (PMID: 29125098) Microbiol Mol Biol Rev. 2011 Sep;75(3):423-33, first page of table of contents. (PMID: 21885679) Adv Appl Microbiol. 2014;89:135-83. (PMID: 25131402) Bioinformatics. 2014 Aug 1;30(15):2114-20. (PMID: 24695404) Nat Rev Microbiol. 2012 Mar 16;10(4):266-78. (PMID: 22421879) Arch Virol. 2007 Feb;152(2):227-43. (PMID: 17051420) Viruses. 2023 Mar 16;15(3):. (PMID: 36992476) J Clin Microbiol. 2015 Dec;53(12):3788-97. (PMID: 26400782) Adv Virus Res. 2012;82:339-49. (PMID: 22420857) Sci Rep. 2019 Apr 30;9(1):6643. (PMID: 31040333) FEMS Microbiol Lett. 2003 Feb 28;219(2):275-83. (PMID: 12620632) Bioinformatics. 2010 Sep 15;26(18):2334-5. (PMID: 20624783) Viruses. 2021 Mar 18;13(3):. (PMID: 33803862) Front Microbiol. 2019 Jan 31;9:3192. (PMID: 30766528) J Bacteriol. 2003 Jun;185(11):3325-32. (PMID: 12754230) mSystems. 2022 Aug 30;7(4):e0001922. (PMID: 35762793) Front Microbiol. 2017 May 09;8:837. (PMID: 28536572) Elife. 2021 Mar 09;10:. (PMID: 33687327) Res Microbiol. 2008 Jun;159(5):406-14. (PMID: 18555669) Virology. 2016 May;492:11-20. (PMID: 26896930) Viruses. 2020 Nov 06;12(11):. (PMID: 33172115) Bioinformatics. 2017 Aug 01;33(15):2379-2380. (PMID: 28379287) Nucleic Acids Res. 2021 Jul 2;49(W1):W293-W296. (PMID: 33885785) Appl Environ Microbiol. 2015 Apr;81(8):2696-705. (PMID: 25662974) Appl Environ Microbiol. 2006 Feb;72(2):1110-7. (PMID: 16461656) Front Microbiol. 2018 Feb 28;9:326. (PMID: 29541067) BMC Genomics. 2008 Feb 08;9:75. (PMID: 18261238) J Antimicrob Chemother. 2020 Dec 1;75(12):3491-3500. (PMID: 32780112) Cell Rep. 2019 Oct 29;29(5):1336-1350.e4. (PMID: 31665644) Sci Rep. 2017 Aug 15;7(1):8292. (PMID: 28811656) Viruses. 2019 Mar 11;11(3):. (PMID: 30862096) Antimicrob Agents Chemother. 2018 Sep 24;62(10):. (PMID: 30104266) J Virol. 1996 Jun;70(6):3678-87. (PMID: 8648702) Antimicrob Agents Chemother. 2020 Aug 20;64(9):. (PMID: 32571816) Infect Immun. 2019 Oct 18;87(11):. (PMID: 31451618) Appl Environ Microbiol. 2000 May;66(5):2263-6. (PMID: 10788414) J Bacteriol. 2021 Oct 12;203(21):e0017721. (PMID: 34370561) J Hist Med Allied Sci. 2018 Oct 1;73(4):385-411. (PMID: 30312428) Antibiotics (Basel). 2022 Aug 30;11(9):. (PMID: 36139953) Infect Immun. 2019 May 21;87(6):. (PMID: 30936157) Microbiol Mol Biol Rev. 2001 Jun;65(2):261-87 ; second page, table of contents. (PMID: 11381102) Microb Drug Resist. 2018 Jun;24(5):590-606. (PMID: 29058560) Mol Microbiol. 2019 Jun;111(6):1463-1475. (PMID: 30811056) Microbiol Resour Announc. 2021 Apr 22;10(16):. (PMID: 33888497) mBio. 2012 Mar 01;3(1):e00318-11. (PMID: 22354958) Virus Res. 2021 Jun;298:198391. (PMID: 33737153) Syst Biol. 2020 Jan 1;69(1):110-123. (PMID: 31127947) Bacteriophage. 2016 Jan 5;6(1):e1096995. (PMID: 27144083) mBio. 2020 Apr 28;11(2):. (PMID: 32345640) BMC Infect Dis. 2011 Mar 31;11:80. (PMID: 21453466) Methods Mol Biol. 2009;501:203-19. (PMID: 19066823) Nat Methods. 2012 Jul;9(7):671-5. (PMID: 22930834) mBio. 2024 Mar 13;15(3):e0339623. (PMID: 38353560) J Glob Antimicrob Resist. 2019 Mar;16:36-47. (PMID: 30149193) Bacteriophage. 2016 Aug 5;6(3):e1219440. (PMID: 27738555) Viruses. 2021 Sep 07;13(9):. (PMID: 34578366) Front Microbiol. 2021 Feb 24;12:616712. (PMID: 33717006) Antimicrob Agents Chemother. 2001 Mar;45(3):649-59. (PMID: 11181338) PLoS Pathog. 2023 Jun 2;19(6):e1011424. (PMID: 37267422) Res Microbiol. 2018 Nov;169(9):531-539. (PMID: 29777835) Methods Mol Biol. 2014;1151:165-88. (PMID: 24838886) |
| فهرسة مساهمة: | Keywords: Appelmans protocol; Enterococcus faecium; host range extension; vancomycin-resistant enterococci; virulent phages |
| المشرفين على المادة: | 6Q205EH1VU (Vancomycin) 0 (Anti-Bacterial Agents) |
| تواريخ الأحداث: | Date Created: 20240409 Date Completed: 20240502 Latest Revision: 20240629 |
| رمز التحديث: | 20240629 |
| مُعرف محوري في PubMed: | PMC11210271 |
| DOI: | 10.1128/aac.01439-23 |
| PMID: | 38591854 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1098-6596 |
|---|---|
| DOI: | 10.1128/aac.01439-23 |